Filtered By:
Specialty: Pharmaceuticals
Management: Partnerships
This page shows you your search results in order of date.
Order by Relevance | Date
Total 20 results found since Jan 2013.
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation
IRVINE, CA – May 8, 2020 – Johnson & Johnson Medical Devices Companies* today announced that Biosense Webster, Inc.’s THERMOCOOL SMARTTOUCH® SF Ablation Catheter, evaluated in the PRECEPT study for the treatment of persistent atrial fibrillation (AF), resulted in freedom from any documented, symptomatic atrial arrhythmias at 15 months post-procedure for eight out of ten study participants (80.4 percent).1 Use of the THERMOCOOL SMARTTOUCH SF CATHETER for persistent atrial fibrillation is investigational only. This PRECEPT study data support a Premarket Approval supplement application to the U.S. Food and Drug Adm...
Source: Johnson and Johnson - May 12, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
St. Elizabeth expands partnership with one of region ’s largest doctor groups
St. Elizabeth Healthcare is expanding its clinical partnership with a neurosurgical physician group to provide more complex interventional stroke and brain tumor services.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 14, 2019 Category: Pharmaceuticals Authors: Barrett J. Brunsman Source Type: news
Cone Health employs teleneurology at MedCenter High Point
Cone Health is implementing technology to better care for High Point patients with stroke, seizure, headaches and other neurological disorders.
MedCenter High Point at 2630 Willard Dairy Road, will use teleneurology to connect doctors and nurses in the emergency department and other areas throughout the hospital with on-call neurologists. The service is part of Cone Health Neurosciences and is a partnership with Atrium Health and TeleS pecialists.
Cone Health says the technology solves two…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 12, 2018 Category: Pharmaceuticals Authors: John Joyce Source Type: news
Brainomix Secures £7m ($9.8m) Investment to Tackle Strokes With AI
Brainomix builds on partnership with Boehringer Ingelheim for AI-assisted fast treatment of stroke victims in latest venture round.
OXFORD, England, April 3, 2018 -- (Healthcare Sales & Marketing Network) -- Brainomix, a medical imaging company using a... Devices, Neurology, Venture Capital Brainomix, Boehringer Ingelheim, stroke, e-ASPECTS
Source: HSMN NewsFeed - April 3, 2018 Category: Pharmaceuticals Source Type: news
Marcus Foundation gives $15 million to create Marcus Stroke Network
The Atlanta-based Marcus Foundation gave $15 million to establish the Marcus Stroke Network, a partnership that includes Grady Health System, Emory University School of Medicine, the American Heart Association/American Stroke Association and Boca Raton Regional Hospitals.
The goal of the network is to reduce stroke disability and death rates in the Southeast, known as the stroke belt because of its unusually high incidence of stroke and other forms of cardiovascular disease.
"The general population…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 22, 2018 Category: Pharmaceuticals Authors: Ellie Hensley Source Type: news
Bayer and Ashfield Meetings & Events scoop ICE Award
The ICE Awards are the only events industry awards open exclusively to in-house corporate event planners. The award success celebrates the partnership between Bayer and Ashfield Meetings & Events. The relationship, now in its fifth year, started with the provision of venue sourcing services and has developed to provide full service solutions including developing communication objectives, creating content and designing different message delivery methods.
Judges cited that the submission was a standout entry in the category. They felt that the submission demonstrated a best practice example of how to approach agency rela...
Source: Ashfield Healthcare News - July 11, 2017 Category: Pharmaceuticals Authors: Ewan Jamieson Tags: Ashfield Source Type: news
Tau Imaging Among Breakthroughs Advancing the Fight against Alzheimer ' s
Worldwide, nearly44 million people now have Alzheimer ' s disease (AD) or related dementia, making these conditions the top cause of disabilities in later life. The biopharma industry has invested billions of dollars into research to treat and prevent AD1, yet this work has faced many obstacles, including difficulty identifying biomarkers, tracking the disease ’s progress in the brain, and recruiting patients to trials while they are still asymptomatic. But in recent years, we’ve begun to see breakthroughs that is driving our research in new directions. Many of these accomplishments were highlighted at the Alzh...
Source: EyeForPharma - September 21, 2016 Category: Pharmaceuticals Authors: Olga Uspenskaya-Cadoz Source Type: news
The Importance of Talent and Chemistry in New Patient-First Business Models
Forward-thinking life sciences companies are shifting to new patient-centered business models, leaving the traditional volume-first approach behind. This move has tremendous implications, not only for patients but also for the current workforce and future talent: life sciences companies need to design new roles and rethink their talent strategies, including the ways they recruit, train, motivate and retain the best teams.The shift from volume to valueThe historical model in life sciences has been based on selling products, where more was better - more products, more market share and then more profits. Value-based reimburse...
Source: EyeForPharma - August 12, 2016 Category: Pharmaceuticals Authors: Jeff Elton Source Type: news
Centaurs, Not Snake Oil
TheTechtour Healthtech Summit hosted by the International Venture Club in Lausanne is a dating event for European seed, start-up and growth companies looking for investment and for Venture capital and some Pharma/Medtech companies looking to invest. Doug Haggstrom went along to take the pulse of European digital health companies. These companies aren ’t specifically focused on Pharma as partners but it is worth paying attention to how digital health products and services are developing. Pharma developed tools and services will, after all, be compared to these companies in the marketplace and the discipline of proving sta...
Source: EyeForPharma - August 2, 2016 Category: Pharmaceuticals Authors: Tina Boggiano Douglas Haggstrom Source Type: news
